Selling subsidiary equity to Hillhouse Capital to fully focus on CRDMO
October 27, 2025
Source: drugdu
161
On October 26, WuXi AppTec (603259/02359) issued an announcement that its wholly-owned subsidiary Shanghai WuXi AppTec New Drug Development Co., Ltd. intends to transfer its 100% equity in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. to Shanghai Shiherong Enterprise Management Consulting Co., Ltd. and Shanghai Shihemu Enterprise Management Consulting Co., Ltd. for a consideration of RMB 2.8 billion.
To focus on the CRDMO (Contract Research, Development and Manufacturing) business model, focusing on drug discovery, laboratory testing, process development and manufacturing services, and accelerating the deployment of global capabilities and production capacity, the company's wholly-owned subsidiary Shanghai WuXi intends to transfer 100% of its equity in Kangde Hongyi and Jinshi Pharmaceutical.To the transferees. The transferees are all newly established companies by Hillhouse Capital through its private equity funds for the purpose of this transaction.
In the first three quarters of 2025, WuXi AppTec achieved revenue of 32.857 billion yuan and net profit attributable to shareholders of the parent company of 12.076 billion yuan.
Source：https://finance.eastmoney.com/a/202510263544433470.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
